| Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. | |
| | |
MedLine Citation:
|
PMID: 12548577 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Osteoporosis is a complication of androgen deprivation therapy in men with prostate carcinoma. Androgen deprivation therapy, caused by either bilateral orchiectomy or treatment with a gonadotropin-releasing hormone agonist, decreases bone mineral density and increases fracture risk. Other factors including diet and lifestyle may contribute to bone loss. There is limited information regarding the best strategy to prevent osteoporosis in men with prostate carcinoma. Lifestyle modification including smoking cessation, moderation of alcohol consumption, and regular weight-bearing exercise should be encouraged. Supplemental calcium and vitamin D are also recommended. Additional treatment may be warranted for men with osteoporosis, fractures, or high rates of bone loss during androgen deprivation therapy. Intravenous pamidronate, a second-generation bisphosphonate, prevents bone loss during androgen deprivation therapy. Zoledronic acid, a more potent third-generation bisphosphonate, not only prevents bone loss but also increases bone mineral density during androgen deprivation therapy. Other bisphosphonates may be effective although they have not been evaluated in this clinical setting. Treatment with estrogens or selective estrogen receptor modulators may also be effective. Monotherapy with bicalutamide or other antiandrogens may cause less bone loss than androgen deprivation therapy. |
| | |
Authors:
|
Matthew R Smith |
Related Documents
:
|
14710507 - New approaches to pharmacological treatment of osteoporosis. 12107657 - An osteoporosis clinical pathway for the medical management of patients with low-trauma... 23162957 - Paediatric acetabular fractures. data from the german pelvic trauma registry initiative. 19891237 - Osteoporosis in patients with systemic lupus erythematosus. 9292597 - Molecular temporal bone pathology: i. historical foundation. 16924367 - Global reconstruction of type iiia open comminuted femoral shaft fracture with segmenta... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Cancer Volume: 97 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 2003 Feb |
Date Detail:
|
Created Date: 2003-01-27 Completed Date: 2003-04-14 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 789-95 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11149 |
Affiliation:
|
Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. smith.matthew@mgh.harvard.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Absorptiometry, Photon Alendronate / therapeutic use Androgen Antagonists / therapeutic use* Anilides / therapeutic use* Bone Density Calcium / therapeutic use Gonadotropin-Releasing Hormone / adverse effects, agonists* Humans Life Style Male Nitriles Orchiectomy / adverse effects* Osteoporosis / diagnosis, etiology, therapy* Prostatic Neoplasms / drug therapy* Tosyl Compounds |
| Chemical | |
Reg. No./Substance:
|
0/Androgen Antagonists; 0/Anilides; 0/Nitriles; 0/Tosyl Compounds; 33515-09-2/Gonadotropin-Releasing Hormone; 66376-36-1/Alendronate; 7440-70-2/Calcium; 90357-06-5/bicalutamide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Role of endothelin-1 in osteoblastic bone metastases.
Next Document: Moving disease biology from the lab to the clinic.